COMPASS Pathfinder Ltd.: COMPASS Pathways announces pricing of public offering
London, UK, 30 April 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) ( COMPASS ), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its public offering of 4,000,000 American Depositary Shares ( ADSs ) representing 4,000,000 ordinary shares at a public offering price of $36.00 per ADS for total gross proceeds of $144.0 million. All ADSs sold in the offering were offered by COMPASS. The offering is expected to close on or about 4 May 2021, subject to the satisfaction of customary closing conditions. In addition, COMPASS has granted the underwriters a 30-day option to purchase up to an additional 600,000 ADSs at the public offering price, less underwriting discounts and commissions.
COMPASS Pathways launches proposed public offering
COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the launch of a proposed public offering of 4,000,000 American Depositary Shares each representing one ordinary share. Each of the ADSs is being offered by COMPASS. COMPASS expects to grant the underwriters a 30-day option to purchase up to an additional 600,000 …
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the launch of a proposed public offering of 4,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share.
COMPASS Pathfinder Ltd : COMPASS Pathways launches proposed public offering finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(0)
Study concludes that psilocybin findings should be explored further in larger studies
London, UK, April 15, 2021(NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).
The study was designed and conducted by a research team at Imperial College London, using COMPASS s COMP360 psilocybin.
This was an exploratory, randomised, double-blind clinical study. Its aim was to compare the efficacy and mechanisms of action of psilocybin with a six-week course of escitalopram, a selective serotonin reuptake inhibitor (SSRI), for MDD.
The study included 59 participants; 30 were randomly assigned to the psilocybin arm, and 29 to the escitalopram arm. Participants in the psilocybin arm received two doses of 25mg psilocybin three weeks apart, with psychological support delivered prior to, during and after each psilocybin administration, plus six weeks of daily placebo caps
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New England Journal of Medicine publishes exploratory study showing signals of positive .
COMPASS Pathfinder Ltd.April 15, 2021 GMT
London, UK, April 15, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).
ADVERTISEMENT
The study was designed and conducted by a research team at Imperial College London, using COMPASS’s COMP360 psilocybin.